甲状腺癌中的 p21 激活激酶。
p21-Activated Kinases in Thyroid Cancer.
机构信息
Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, and Cancer Biology Program, The Ohio State University College of Medicine and Arthur G. James Comprehensive Cancer Center, Columbus, Ohio.
Department of Hematology and Medical Oncology, Emory University and Winship Cancer Institute, Atlanta, Georgia.
出版信息
Endocrinology. 2020 Aug 1;161(8). doi: 10.1210/endocr/bqaa105.
Abstract
The family of p21-activated kinases (PAKs) are oncogenic proteins that regulate critical cellular functions. PAKs play central signaling roles in the integrin/CDC42/Rho, ERK/MAPK, PI3K/AKT, NF-κB, and Wnt/β-catenin pathways, functioning both as kinases and scaffolds to regulate cell motility, mitosis and proliferation, cytoskeletal rearrangement, and other cellular activities. PAKs have been implicated in both the development and progression of a wide range of cancers, including breast cancer, pancreatic melanoma, thyroid cancer, and others. Here we will discuss the current knowledge on the structure and biological functions of both group I and group II PAKs, as well as the roles that PAKs play in oncogenesis and progression, with a focus on thyroid cancer and emerging data regarding BRAF/PAK signaling.
摘要
p21 激活激酶（PAKs）家族是致癌蛋白，调节关键的细胞功能。PAKs 在整合素/CDC42/Rho、ERK/MAPK、PI3K/AKT、NF-κB 和 Wnt/β-catenin 通路中发挥核心信号作用，既是激酶又是支架，调节细胞迁移、有丝分裂和增殖、细胞骨架重排和其他细胞活动。PAKs 参与了广泛的癌症的发展和进展，包括乳腺癌、胰腺黑色素瘤、甲状腺癌等。在这里，我们将讨论关于 I 组和 II 组 PAKs 的结构和生物学功能的最新知识，以及 PAKs 在致癌和进展中的作用，重点关注甲状腺癌和关于 BRAF/PAK 信号的新兴数据。
相似文献
1
p21-Activated Kinases in Thyroid Cancer.甲状腺癌中的 p21 激活激酶。
Endocrinology. 2020 Aug 1;161(8). doi: 10.1210/endocr/bqaa105.
2
MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.MAPK 和 AKT 激活的甲状腺癌对 I 组 PAK 抑制敏感。
Endocr Relat Cancer. 2019 Aug;26(8):699-712. doi: 10.1530/ERC-19-0188.
3
P21 activated kinase signaling in cancer.P21 激活激酶信号通路与癌症。
Semin Cancer Biol. 2019 Feb;54:40-49. doi: 10.1016/j.semcancer.2018.01.006. Epub 2018 Jan 9.
4
Development of p21 activated kinase-targeted multikinase inhibitors that inhibit thyroid cancer cell migration.靶向 p21 激活激酶的多激酶抑制剂的开发，可抑制甲状腺癌细胞迁移。
J Clin Endocrinol Metab. 2013 Aug;98(8):E1314-22. doi: 10.1210/jc.2012-3937. Epub 2013 May 24.
5
Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion.I 组 p21 激活激酶调节甲状腺癌细胞迁移，并且在甲状腺癌侵袭中过表达和激活。
Endocr Relat Cancer. 2010 Oct 29;17(4):989-99. doi: 10.1677/ERC-10-0168. Print 2010 Dec.
6
BRAF activates and physically interacts with PAK to regulate cell motility.BRAF激活PAK并与其发生物理相互作用以调节细胞运动。
Endocr Relat Cancer. 2014;21(6):865-77. doi: 10.1530/ERC-14-0424. Epub 2014 Sep 16.
7
p21-Activated kinases as promising therapeutic targets in hematological malignancies.p21-激活的激酶作为血液系统恶性肿瘤有前途的治疗靶点。
Leukemia. 2022 Feb;36(2):315-326. doi: 10.1038/s41375-021-01451-7. Epub 2021 Oct 25.
8
p21-activated kinases and gastrointestinal cancer.p21激活激酶与胃肠道癌
Biochim Biophys Acta. 2013 Jan;1833(1):33-9. doi: 10.1016/j.bbamcr.2012.10.015. Epub 2012 Oct 22.
9
Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer.第二组p21激活激酶作为胃肠道癌的治疗靶点。
World J Gastroenterol. 2016 Jan 21;22(3):1224-35. doi: 10.3748/wjg.v22.i3.1224.
10
PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.PAK信号传导驱动BRAF突变型黑色素瘤对MAPK抑制剂产生获得性耐药。
Nature. 2017 Oct 5;550(7674):133-136. doi: 10.1038/nature24040. Epub 2017 Sep 27.
引用本文的文献
1
Differential activity of specific inhibitors of transcription regulating cyclin-dependent kinases in thyroid cancer cells.转录调节细胞周期蛋白依赖性激酶的特异性抑制剂在甲状腺癌细胞中的差异活性。
Endocr Relat Cancer. 2025 May 29;32(6). doi: 10.1530/ERC-24-0124. Print 2025 Jun 1.
2
CDK5 targets p21 to regulate thyroid cancer cell proliferation and malignancy in patients.细胞周期蛋白依赖性激酶5作用于p21以调控甲状腺癌患者癌细胞的增殖和恶性程度。
Mol Med Rep. 2025 Jul;32(1). doi: 10.3892/mmr.2025.13547. Epub 2025 Apr 25.
3
Identification of a novel immune checkpoint-related gene signature predicts prognosis and immunotherapy in breast cancer and experiment verification.一种新型免疫检查点相关基因特征的鉴定可预测乳腺癌的预后及免疫治疗效果并进行实验验证。
Sci Rep. 2024 Dec 28;14(1):31065. doi: 10.1038/s41598-024-82266-1.
4
Tasquinimod promotes the sensitivity of ovarian cancer cells to cisplatin by down-regulating the HDAC4/p21 pathway.他喹莫德通过下调HDAC4/p21信号通路提高卵巢癌细胞对顺铂的敏感性。
Korean J Physiol Pharmacol. 2025 Mar 1;29(2):191-204. doi: 10.4196/kjpp.24.132. Epub 2024 Nov 14.
5
FOXA1, induced by RC48, regulates HER2 transcription to enhance the tumorigenic capacity of lung cancer through PI3K/AKT pathway.由RC48诱导的FOXA1通过PI3K/AKT途径调节HER2转录，以增强肺癌的致瘤能力。
J Cancer. 2024 Sep 16;15(18):5863-5875. doi: 10.7150/jca.100210. eCollection 2024.
6
Inhibition of NAMPT by PAK4 Inhibitors.PAK4 抑制剂对 NAMPT 的抑制作用。
Int J Mol Sci. 2024 Sep 21;25(18):10138. doi: 10.3390/ijms251810138.
7
FRAX486, a PAK inhibitor, overcomes ABCB1-mediated multidrug resistance in breast cancer cells.FAX486，一种 PAK 抑制剂，克服了乳腺癌细胞中 ABCB1 介导的多药耐药性。
Braz J Med Biol Res. 2024 Jul 1;57:e13357. doi: 10.1590/1414-431X2024e13357. eCollection 2024.
8
Cdc42 Regulates the Expression of Cytoskeleton and Microtubule Network Proteins to Promote Invasion and Metastasis of Progeny Cells Derived from CoCl-induced Polyploid Giant Cancer Cells.Cdc42调控细胞骨架和微管网络蛋白的表达以促进氯化钴诱导的多倍体巨癌细胞衍生的子代细胞的侵袭和转移。
J Cancer. 2023 Jun 26;14(10):1920-1934. doi: 10.7150/jca.85032. eCollection 2023.
9
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer.Pak1信号通路的过度激活介导雌激素受体阳性（ER+）乳腺癌对内分泌治疗和CDK4/6抑制剂的耐药性。
NPJ Breast Cancer. 2023 May 31;9(1):48. doi: 10.1038/s41523-023-00556-9.
10
Potential Resistance to Antineoplastic Aminated Fullerenes Mediated by M2-Like Monocyte-Derived Exosomes.M2样单核细胞衍生外泌体介导的对抗肿瘤胺化富勒烯的潜在抗性
Front Oncol. 2022 Mar 31;12:779939. doi: 10.3389/fonc.2022.779939. eCollection 2022.
本文引用的文献
1
Rising Incidence and Incidence-Based Mortality of Thyroid Cancer in California, 2000-2017.加利福尼亚州 2000-2017 年甲状腺癌的发病率和发病率死亡率上升。
J Clin Endocrinol Metab. 2020 Jun 1;105(6). doi: 10.1210/clinem/dgaa121.
2
Targeting effector pathways in RAC1-driven malignant melanoma.靶向 RAC1 驱动的恶性黑色素瘤中的效应通路。
Small GTPases. 2021 Jul;12(4):273-281. doi: 10.1080/21541248.2020.1728469. Epub 2020 Feb 17.
3
Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance.针对 8505C 间变性甲状腺癌细胞中的 XPO1 和 PAK4：克服仑伐替尼治疗耐药性的潜在意义。
Int J Mol Sci. 2019 Dec 29;21(1):237. doi: 10.3390/ijms21010237.
4
Src-Dependent DBL Family Members Drive Resistance to Vemurafenib in Human Melanoma.Src 依赖性 DBL 家族成员驱动人黑色素瘤对维莫非尼的耐药性。
Cancer Res. 2019 Oct 1;79(19):5074-5087. doi: 10.1158/0008-5472.CAN-19-0244. Epub 2019 Aug 15.
5
RAC1 Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance.RAC1 通过血清反应因子诱导间充质表型转换，促进黑色素瘤的发展和治疗耐药性。
Cancer Cell. 2019 Jul 8;36(1):68-83.e9. doi: 10.1016/j.ccell.2019.05.015. Epub 2019 Jun 27.
6
MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.MAPK 和 AKT 激活的甲状腺癌对 I 组 PAK 抑制敏感。
Endocr Relat Cancer. 2019 Aug;26(8):699-712. doi: 10.1530/ERC-19-0188.
7
Solution structures and biophysical analysis of full-length group A PAKs reveal they are monomeric and auto-inhibited in .全长 A 族 PAK 的溶液结构和生物物理分析表明，它们是单体形式，并在. 中处于自身抑制状态。
Biochem J. 2019 Apr 4;476(7):1037-1051. doi: 10.1042/BCJ20180867.
8
Group I Paks are essential for epithelial- mesenchymal transition in an Apc-driven model of colorectal cancer.I 型帕克斯蛋白对于 APC 驱动的结直肠癌模型中的上皮间质转化是必需的。
Nat Commun. 2018 Aug 27;9(1):3473. doi: 10.1038/s41467-018-05935-6.
9
P21 activated kinase signaling in cancer.P21 激活激酶信号通路与癌症。
Semin Cancer Biol. 2019 Feb;54:40-49. doi: 10.1016/j.semcancer.2018.01.006. Epub 2018 Jan 9.
10
Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors.A 组 PAK 抑制剂抑制 RAC1 驱动的恶性黑色素瘤。
Oncogene. 2018 Feb 15;37(7):944-952. doi: 10.1038/onc.2017.400. Epub 2017 Oct 23.
Zotero 插件